Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
IPO Year: 1992
Exchange: NASDAQ
Website: gilead.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2026 | $165.00 | Hold → Buy | Maxim Group |
| 3/10/2026 | $180.00 | Buy | Jefferies |
| 2/20/2026 | $155.00 | Equal Weight | Barclays |
| 2/11/2026 | $140.00 → $170.00 | Buy | Needham |
| 1/7/2026 | $145.00 | Buy | UBS |
| 11/24/2025 | $140.00 | Buy | Truist |
| 11/13/2025 | $140.00 | Sector Outperform | Scotiabank |
| 8/19/2025 | $128.00 | Neutral → Outperform | Daiwa Securities |
| 8/8/2025 | $127.00 | Hold → Buy | Truist |
| 7/25/2025 | $133.00 | Hold → Buy | Needham |
Fastest customizable press release news feed in the world
– IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA – – 52-Week Results Demonstrate High and Sustained ALP Normalization and Generally Well-Tolerated Safety Profile – – Findings Add to Growing Evidence Supporting ALP Normalization as an Achievable Treatment Goal in PBC – Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 we
– ALP Is a Key Marker of Disease Activity in People Living With PBC, With Elevations Above Normal Associated with Increased Risk of Disease Progression – – Further Analyses of the Phase 3 ASSURE Study Demonstrate Sustained ALP Normalization and Show Exploratory Outcomes of Stable or Improved Liver Stiffness, Providing Supportive, Long-term Evidence – Gilead Sciences, Inc. (NASDAQ:GILD) today shared new results from a post hoc analysis showing that Livdelzi® (seladelpar) was associated with high and sustained rates of normalization of a key liver marker (ALP) in people living with primary biliary cholangitis (PBC). In an ongoing Phase 3 study, participants with elevated ALP levels (betwe
– Chronic HDV is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure and liver-related death – – Approval introduces the first FDA-approved therapy for this disease with limited treatment options and high unmet need – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex® (bulevirtide-gmod) 8.5 mg for the treatment of adults living with chronic hepatitis delta virus (HDV) infection, making it the first and only approved treatment for HDV in the United States. The FDA granted accelerated approval to Hepcludex based on reductions in HDV RNA
– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients– – Positive Opinion Marks a Significant Step Towards Introducing a Crucial First-line Treatment Option for People Living with Metastatic Triple-Negative Breast Cancer in the EU – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult
– ASCO Presentations on Trodelvy® in First-line Metastatic Triple-Negative Breast Cancer and Anito-cel in Relapsed or Refractory Multiple Myeloma Build Toward Potential Commercial Launches – – EHA Updates Include Durability of KITE-753, Kite's Enhanced DuoCore™ CAR T-cell Therapy – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, including six oral presentations, at the 2026 ASCO Annual Meeting (May 29 – June 2) and the 2026 EHA Congress (June 11 – 14). These presentations underscore the increasing diversity of Gilead's oncology portfolio and pipeline reflecting a growing body of evidence across both s
– Acquisition Builds on Gilead's Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform – Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs). The acquisition brings Gilead next-generation ADC assets and a platform designed to maximize patient benefit through more selective delivery of diverse payloads to tumors. Tubulis' technologies enable the development of unique ADCs with superior biophysical properties, capable of achieving robus
- The disease remains a public health challenge with an estimated 50,000 to 90,000 new cases each year - Gilead Sciences, Inc. (NASDAQ:GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic support and product donations to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. VL, the second deadliest parasitic disease after malaria, is a sandfly-borne illness that attacks internal organs and can be fatal if untreated. The expanded agreement aims to improve access to life-saving diagnostic services and treatment for some of the world's most vulnerable communities, with a sharpe
Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturing in 2031 and $500 million of 4.900% senior notes maturing in 2034. The offering is expected to close on May 20, 2026, subject to customary closing conditions. Gilead intends to use the net proceeds from this offering for general corpor
- Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers - - Bulevirtide Data Strengthen Evidence of Efficacy and Safety Across Broad HDV Populations - - New Findings Highlight Progress Toward HCV Elimination and Improved HDV Risk Insight - Gilead Sciences, Inc. (NASDAQ:GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and lo
Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the first quarter 2026. "Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Building on the strongest pipeline in Gilead's history, we are adding potentially best-in-disease assets and platforms in oncolog
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Maxim Group upgraded Gilead Sciences from Hold to Buy and set a new price target of $165.00
Jefferies initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $180.00
Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00
Needham reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $170.00 from $140.00 previously
UBS resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $145.00
Truist resumed coverage of Gilead Sciences with a rating of Buy and set a new price target of $140.00
Scotiabank initiated coverage of Gilead Sciences with a rating of Sector Outperform and set a new price target of $140.00
Daiwa Securities upgraded Gilead Sciences from Neutral to Outperform and set a new price target of $128.00
Truist upgraded Gilead Sciences from Hold to Buy and set a new price target of $127.00
Needham upgraded Gilead Sciences from Hold to Buy and set a new price target of $133.00
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)
144 - GILEAD SCIENCES, INC. (0000882095) (Subject)
FWP - GILEAD SCIENCES, INC. (0000882095) (Subject)
424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)
13F-HR - GILEAD SCIENCES, INC. (0000882095) (Filer)
S-8 - GILEAD SCIENCES, INC. (0000882095) (Filer)
10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for GILEAD SCIENCES INC's drug HEPCLUDEX (ORIG-1) with active ingredient BULEVIRTIDE-GMOD) has changed to 'Approval' on 05/22/2026. Application Category: BLA, Application Number: 761468, Application Classification:
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-20) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 10/08/2024. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-7) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215974, Application Classification: Labeling
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-5) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 215973, Application Classification: Labeling
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - GILEAD SCIENCES, INC. (0000882095) (Reporting)
Live finance-specific insights
Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the first quarter 2026. "Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "Building on the strongest pipeline in Gilead's history, we are adding potentially best-in-disease assets and platforms in oncolog
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (NASDAQ:ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx's successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and elim
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2026 financial results and guidance will be released on Thursday, May 7, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2026 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The compa
– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together the resources and expertise of both PEPFAR and The Global Fund is a key component of Gilead's larger coordinated efforts to
– Acquisition Adds TUB-040, a NaPi2b Targeting ADC for Ovarian Cancer and other Solid Tumors, to Gilead Pipeline – – Industry Leading ADC Platform That Includes its Clinically-Validated Tubutecan Linker-Payload Technology and Next-Generation Platform to Expand Gilead's ADC Capabilities – Gilead Sciences, Inc. (NASDAQ:GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), building on Gilead's oncology pipeline, focused on addressing areas of high unmet need. This press release features multimedia. View the full release here: https:/
– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – Gilead Sciences, Inc. (NASDAQ:GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities af
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi
Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $14.3 billion for Full Year 2025 Gilead Sciences, Inc. (NASDAQ:GILD) announced today its results of operations for the fourth quarter and full year 2025. "Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "In 2026, our potential new launches include two cancer therapies and an additional HIV
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a health
Arrivals of the twice-yearly PrEP option in Eswatini and Zambia mark an important milestone in the goal of ending the HIV epidemic in sub-Saharan Africa Gilead Sciences, Inc. (NASDAQ:GILD) today announced the delivery of first shipments of lenacapavir – Gilead's twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people living with HIV globally. "The arrivals of the first doses of lenacapavir in Eswatini and Zambia mark an im
Live Leadership Updates
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead's senior leadership team. Dr. Berger succeeds Merdad Parsey, MD, PhD. Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He will assume responsibility for the Company's leading virology, oncology and inflammation portfolio and will oversee the company's global Development and Medical Affairs organizations. "Dietmar's exceptional leadership in
Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead's senior leadership team, effective May 30. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005214/en/Gilead Appoints Cindy Perettie Executive Vice President of Kite (Photo: Business Wire) Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care. Most recently, she was Head of Roche's Molecular Lab Solutions where she oversaw the PCR (polymerase chain reactio
MONTREAL, Nov. 29, 2022 /PRNewswire/ - Thryv Therapeutics Inc. is pleased to announce the appointment of Melissa Koomey to its Board of Directors. Ms. Koomey brings an impressive depth of experience in product commercialization, launch and marketing execution, which will be crucial as Thryv advances its development programs in rare arrhythmias such as Long QT Syndrome and advanced cancers. "We are excited to have Melissa join the Thryv Board of Directors at this pivotal time in our story. Our lead compound will emerge from initial safety studies early in 2023 and we will accelerate into efficacy trials with Melissa's experience and insights in Long QT Syndrome," said Paul F. Truex, Thryv's
– Brett Pletcher, Executive Vice President, Corporate Affairs and General Counsel to Retire After 17 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Deborah Telman will join the company as Executive Vice President, Corporate Affairs and General Counsel, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Ms. Telman will assume responsibility for Gilead's legal and corporate affairs function, which includes government and policy, and public affairs. Ms. Telman will start in her new role August 1, 2022. She will also become Corporate Secretary of Gilead. Ms. Telman will succeed Brett Plet
– Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead – Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company's senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O'Day. Dr. Ma will assume responsibility for Gilead's Pharmaceutical Development and Manufacturing organization effective July 18, 2022. Dr. Ma will succeed Dr. Yang, who is retiring from Gilead after nearly three decades. Dr. Ma brings to her new role more than 25 years of ex
Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Robin L. Washington as an independent director effective May 12, 2022. Ms. Washington is among the most experienced business leaders in the biopharmaceutical and technology industries, having served as Chief Financial Officer at Gilead, Inc. from 2008 until 2019, managing global finance, investor relations, facilities and operations, and information technology during a period when corporate revenue grew by more than six-fold. This press release features multimedia. View the full
This live feed shows all institutional transactions in real time.
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES, INC. (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)
SC 13G/A - GILEAD SCIENCES INC (0000882095) (Subject)